Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. - Wikidata - awgldk - TriplyDB

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

http://www.wikidata.org/entity/Q33976477

about

Non-alcoholic fatty liver disease: what the clinician needs to know.Differential clinical profile of candesartan compared to other angiotensin receptor blockers Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b Telmisartan and cardioprotection Partial agonist, telmisartan, maintains PPARγ serine 112 phosphorylation, and does not affect osteoblast differentiation and bone mass Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function Structural basis for telmisartan-mediated partial activation of PPAR gamma Role and therapeutic potential of G-protein coupled receptors in breast cancer progression and metastases Review article: the metabolic syndrome and non-alcoholic fatty liver disease Effect of telmisartan in experimentally induced diabetetes mellitus in rats Telmisartan protects 5/6 Nx rats against renal injury by enhancing nNOS-derived NO generation via regulation of PPARγ signaling Telmisartan induces growth inhibition, DNA double-strand breaks and apoptosis in human endometrial cancer cells eMatchSite: sequence order-independent structure alignments of ligand binding pockets in protein models Left Ventricular Hypertrophy in Pediatric Hypertension: A Mini Review Method for comparing the structures of protein ligand-binding sites and application for predicting protein-drug interactions.Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant kidney mouse model Candesartan, an angiotensin II AT₁-receptor blocker and PPAR-γ agonist, reduces lesion volume and improves motor and memory function after traumatic brain injury in mice.Inhibitors of difficult protein-protein interactions identified by high-throughput screening of multiprotein complexes.Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan.Thiazolidinedione-independent activation of peroxisome proliferator-activated receptor γ is a potential target for diabetic macrovascular complications.eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.Endothelial and vascular muscle PPARgamma in arterial pressure regulation: lessons from genetic interference and deficiency.Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats.Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.Pharmacophore-driven identification of PPARγ agonists from natural sources.Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome Cardiac phenotype and angiotensin II levels in AT1a, AT1b, and AT2 receptor single, double, and triple knockouts.Telmisartan protects central neurons against nutrient deprivation-induced apoptosis in vitro through activation of PPARγ and the Akt/GSK-3β pathway.Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system.Antihypertensive drugs and glucose metabolism Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor.Endothelial progenitor cells in cardiovascular diseases.Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.To compare the effect of Telmisartan with Metoprolol on arterial stiffness in hypertension: prospective randomized parallel group trial.Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway.AGTR1 as a therapeutic target in ER-positive and ERBB2-negative breast cancer cases.

P2860

Q24563068-D930D93C-0AFF-4513-B9B9-C643514658AA Q24613321-99FBE4B0-59C2-46E1-B017-9D5865C74729 Q24645442-2528F84C-A7E8-4E1A-A7E6-01B5331DC1FF Q24816197-5FF850B1-8395-4E2A-A695-B55668863523 Q25257883-B78B750D-2815-461E-8377-6169C21F1BAA Q26861422-43F01061-F9E3-4CD2-832A-A4AF76DB2E7A Q27334866-5921AB2C-2D1D-4CB6-B160-A43DF806A258 Q27437610-5E870BD3-0ABC-4CD5-8380-708994103824 Q27677426-601A65ED-5E32-4374-A969-0763C92B520E Q28084420-4F36908B-357C-4551-A239-F1AC94FE6D99 Q28192695-CC72F22A-5D80-4160-BC45-4086CAD4DF42 Q28387360-EF41C791-BEFB-428D-9242-EE8BB5000900 Q28396739-795D199C-71BE-4825-B146-5556FB9F298D Q28541515-1A6BB164-7EC3-4BBA-9D26-B758BE30E898 Q28543048-DA2D8AE6-17FA-4F9A-B195-063F0EFCD0B1 Q30234333-BFCE915E-EE81-45E4-8E51-CD90EB278A9D Q30367299-8FEBEFD1-5B77-48D6-A42D-88FF5DA3757B Q30501039-D5B829CA-6165-4126-B845-9744537576BF Q30528431-BC77E1D3-FDCB-4A37-9CC0-7A996D6A710C Q30546915-F9C749C3-16BA-4A35-BAF1-125067D282E9 Q33166521-6C56F3D5-8186-4B9A-A73D-094FD1E3D8EB Q33384087-96370747-DC9C-4154-A050-FEE9AB3EAAAE Q33585657-70309DAC-3F48-4A7A-A131-CBCD23050E57 Q33597090-C25D9C47-0383-4A3A-9D16-0D1D9E0AD67B Q33642053-6A68D591-752D-4968-9CB4-6733AB583DCB Q33648966-ACFD678F-6857-4F90-A609-C8A1A7A0E5BB Q33673698-819F78B3-88B2-4049-BA83-B2487BB977C9 Q33689466-6CD9CF9D-AA73-468F-AAE0-3B48D689A8C9 Q33744181-B172F822-C325-420E-8BB7-A9933DFD87B6 Q33840829-A1C62D1A-BE03-427D-A4B9-7F8BB270A9E8 Q33844005-FEDBB4A8-1441-406D-8ADE-C78CDD4ABB65 Q33861931-C820BD96-0A0E-4CF3-95D0-D71B3D6A0A22 Q33935032-2F296E08-CD4A-4052-A3A1-0150FB12AFF2 Q33948469-7E4E880F-F1AF-4F81-9E8F-D3366209A0F1 Q34007211-CD89A1A1-5F96-4E56-9778-21EDD807DCD4 Q34038864-C9688942-9E15-4B64-BD13-FF81F2C27EE0 Q34068447-4B89C56F-2A8F-4257-93C0-EEFF8378285C Q34112656-51CD2A2F-61CC-462B-BE89-4BDA27312C90 Q34115852-1C9562CB-1063-4921-88B5-6997F9EC808F Q34133185-8B9EFE16-3BC1-4C26-B20A-B1A27E8C1B43

P2860

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity.

http://www.wikidata.org/entity/Q33976477

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Identification of telmisartan ...... PPARgamma-modulating activity.

@ast

Identification of telmisartan ...... PPARgamma-modulating activity.

@en

type

label

Identification of telmisartan ...... PPARgamma-modulating activity.

@ast

Identification of telmisartan ...... PPARgamma-modulating activity.

@en

prefLabel

Identification of telmisartan ...... PPARgamma-modulating activity.

@ast

Identification of telmisartan ...... PPARgamma-modulating activity.

@en

P1433

Q33976477-BBE345F0-5627-479F-8D0B-281F58B68EE8

P1476

Q33976477-07186112-27B9-42DD-A542-8F06654B3838

P2093

Q33976477-1D8F015B-175A-4D60-BDDC-515609F610B7

Q33976477-20D6A7FF-7601-4056-A382-2C604FD8B6E9

Q33976477-3423DEFC-B588-4829-B448-879962DE9D68

Q33976477-4831F38D-4C06-4DBF-826F-92F13F1BC8C3

Q33976477-5A2D0F10-196C-42D2-8297-751C7CD8137A

Q33976477-8262EE52-9852-4EB6-8926-5559966F851B

Q33976477-90A3325F-442C-47B9-91B0-893D0E109E80

Q33976477-9F8C4FD3-F2A9-4DA4-8190-678824279FDA

Q33976477-B315A01D-D361-4236-B2EC-F69D6769DF55

Q33976477-B6424AE4-D8B8-44E7-A76D-577F6609E180

P304

Q33976477-B61E5186-0E85-46C7-9BFB-8A2AE367E785

P31

Q33976477-50758702-3B19-48A6-A47F-6BC296B91533

P356

Q33976477-8A4AF33A-7C67-4D33-B573-26694CBBFC37

P407

Q33976477-8A8814DC-F35E-49DE-9317-9E69B615CFD2

P433

Q33976477-D9BCAF89-983E-4065-8BD2-A2838AD30768

P478

Q33976477-CF83C28F-F775-4517-ABD5-FE8A046A3CA8

P577

Q33976477-A3BDA815-608D-4BA8-A20C-03DDB8B4B07E

P5875

Q33976477-634511F0-7AD2-4BC0-B556-68B2147C8114

P698

Q33976477-AEA7EDBC-15DF-4DD4-99E3-3DB7F5A4139C

P356

01.HYP.0000123072.34629.57

P1433

P1476

Identification of telmisartan ...... PPARgamma-modulating activity.

@en

P2093

Amar Chittiboyina

http://www.w3.org/2001/XMLSchema#string

Christopher I Ho

http://www.w3.org/2001/XMLSchema#string

Harrihar A Pershadsingh

http://www.w3.org/2001/XMLSchema#string

Jiaming Wang

http://www.w3.org/2001/XMLSchema#string

Michal Pravenec

http://www.w3.org/2001/XMLSchema#string

Mitchell A Avery

http://www.w3.org/2001/XMLSchema#string

Nianning Qi

http://www.w3.org/2001/XMLSchema#string

Prashant Desai

http://www.w3.org/2001/XMLSchema#string

Stephen C Benson

http://www.w3.org/2001/XMLSchema#string

Theodore W Kurtz

http://www.w3.org/2001/XMLSchema#string

P304

993-1002

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.HYP.0000123072.34629.57

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7789453

http://www.w3.org/2001/XMLSchema#string

P698

15007034

http://www.w3.org/2001/XMLSchema#string